Volume 7, Number 6—December 2001
Research
Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination
Table 2
Age (years) | No. doses | No. OAEa | OAE reports/100,000 doses | RRR (95% CI) | No. SyAEb | SyAE reports/ 100,000 doses | RRR (95% CI) |
---|---|---|---|---|---|---|---|
15-24 | 189,991 | 11 | 5.79 | 2.5 (1.2-5.5) | 3 | 1.58 | 1.0 (0.3-3.6) |
25-44 | 702,783 | 16 | 2.28 | Ref. | 11 | 1.57 | Ref. |
45-64 | 442,605 | 8 | 1.81 | 0.8 (0.3-1.9) | 12 | 2.71 | 1.7 (0.8-3.9) |
65-74 | 86,222 | 1 | 1.16 | 0.5 (0.1-3.8) | 5 | 5.80 | 3.7 (1.3-10.7) |
>75 | 22,085 | 0 | 0 | undefined | 4 | 18.11 | 11.6 (3.7-36) |
Total | 1,443,686 | 36 | 2.49 | 35 | 2.42 |
CI = confidence intervals; Ref = reference.
aOAE: other adverse event (uncomplicated neurologic/systemic, hypersensitivity, or local reaction).
bSyAE: systemic adverse event (multisystemic [excluding anaphylactic] or neurologic reaction).
1Jeff Altman, University of Washington, Seattle, Washington; Vernon Ansdell, Kaiser Permanente, Honolulu, Hawaii; Elizabeth Barnett, Boston University, Boston, Massachusetts; Michele Barry Yale University, New Haven, Connecticut; Bradley Connor, Cornell University, New York, New York; David Freedman, University of Alabama at Birmingham, Birmingham, Alabama; Alejandra Gurtman, Mount Sinai Medical Center, New York, New York; Elaine Jong, University of Washington, Seattle, Washington; Phyllis Kozarsky, Emory University, Atlanta, Georgia; Russell McMullen, University of Washington, Seattle, Washington; Jan Patterson, University of Texas, San Antonio, Texas; Bradley Sack, Johns Hopkins University, Baltimore, Maryland; Mary E. Wilson, Harvard University, Cambridge, Massachusetts; Martin Wolfe, Traveler's Medical Service of Washington, Washington, D.C.